Characterization of type I 5α-reductase activity in DU145 human prostatic adenocarcinoma cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 2, 1996, Pages 195-205

  Kaefer, Martin ^b   Audia, James E ^a   Bruchovsky, Nicholas ^c   Goode, Robin L ^a   Hsiao, Kenneth C ^a   Leibovitch, Ilan Y ^b   Krushinski, Joseph H ^a   Lee, Chung ^d   Steidle, Christopher P ^b   Sutkowski, Debra M ^a   Neubauer, Blake Lee ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPRISTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR;

AEROBIC METABOLISM; ANDROGEN METABOLISM; ARTICLE; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NORTHERN BLOTTING; PANCREAS CELL; PROSTATE; PROSTATE ADENOCARCINOMA; SCALP; SKIN;

EID: 3042981033     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00020-9     Document Type: Article

References (39)

1. 1. Wilson J. D., Griffin J. E. and Russell D. W.: Steroid 5α-reductase 2 deficiency. Endocr. Rev. 14 (1993) 577-593.
2. 2. Bruchovsky N. and Wilson J. D.: The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem. 243 (1968) 2012-2021.
3. 3. Wilbert D. M., Griffin J. E. and Wilson J. D.: Characterization of the cytosol androgen receptor of the human prostate. J. Clin. Endocr. Metab. 56 (1983) 113-120.
4. 4. Adachi K. and Kano M.: Adenyl cyclase in human hair follicles: its inhibition by dihydrotestosterone. Biochem. Biophys. Res. Commun. 41 (1970) 884-890.
5. 5. Bruchovsky N., Rennie P. S., Batzold F, H., Goldenberg S. L., Fletcher T. and McLoughlin M. G.: Kinetic parameters of 5α-reductase activity in stroma and epithelium of normal, hyperplastic and carcinomatous human prostates. J. Clin. Endocr. Metab. 67 (1988) 806-816.
6. 6. Andersson S., Bishop R. W. and Russell D. W.: Expression cloning and regulation of steroid 5α-reductase, an enzyme essential for male sexual differentiation. J. Biol. Chem. 264 (1989) 16249-16255.
7. 7. Andersson S., Berman D. M., Jenkins E. P. and Russell D. W.: Deletion of steroid 5α-reductase 2 in male pseudohermaphroditism. Nature 354 (1991) 159-161.
8. 8. Martini L., Zoppi S. and Motta M.: Studies on the possible existence of two 5 alpha-reductases in the rat prostate. J. Steroid Biochem. 24 (1986) 177-182.
9. 9. Moore R. J. and Wilson J. D.: Steroid 5 alpha-reductase in cultured human fibroblasts. Biochemical and genetic evidence for two distinct enzyme activities. J. Biol. Chem. 251 (1976) 5895-5900.
10. 10. Thigpen A. E., Silver R. I., Guileyardo J. M., Casey M. L., McConnell J. D. and Russell D. W.: Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J. Clin. Invest. 92 (1993) 903-910.
11. 11. Imperato-McGinley J., Guerrero L., Gautier T. and Paterson R. E.: Steroid 5 alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186 (1974) 1213-1217.
12. 12. Thigpen A. E., Davis D. L., Milatovich A., Mendonca B. B., Imperato-McGinley J., Griffin J. E., Francke U., Wilson J. D. and Russell D. W.: Molecular genetics of steroid 5α-reductase 2 deficiency. J. Clin. Invest. 90 (1992) 799-809.
13. 13. Normington K. and Russell D. W.: Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. J. Biol. Chem. 267 (1992) 19548-19554.
14. 14. Brooks J. R., Berman C., Primka R. L., Reynolds G. F. and Rasmusson G. H.: 5 Alpha-reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat. Steroids 47 (1986) 1-19.
15. 15. Lamb J. C., English H., Levandoski P. L., Rhodes G. R., Johnson R. K. and Isaacs J. T.: Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK&F105657: role for testosterone in the androgenic response. Endocrinology 130 (1992) 685-694.
16. 16. Gormley G. J., Stoner E., Bruskewitz R. C., Imperato-McGinley J., Walsh P. C., McConnell J. D., Andriole G. L., Geller J., Bracken B. R., Tenover J. S., Vaughn E. D., Pappas F., Taylor A., Binkowitz B., Ng J. and Group F. S.: The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 327 (1992) 1185-1191.
17. 17. Stoner E. and Group F. S.: The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J. Urol. 147 (1992) 1298-1302.
18. 18. Hirsch K. S., Jones C. D., Audia J. E., Andersson S., McQuaid L., Neubauer B. L., Pike A. J., Pennington P. A., Stamm N. B., Toomey R. E. and Russell D. W.: LY191704: A selective, non-steroidal inhibitor of human steroid 5α-reductase type I. Proc. Natn. Acad. Sci. U.S.A. 90 (1993) 5277-5281.
19. 19. Holt D. A., Levy M. A., Oh H.-Y., Erb J. M., Heaslip J. I., Brandt M. and Lan-Hargest H.-Y.: Inhibition of steroid 5 alpha-reductase by unsaturated 3-carboxysteroids. J. Med. Chem. 33 (1990) 943-950.
20. 20. Jones C. D., Audia J. E., Hirsch K. S., Lawhorn D. E., McQuaid L. A., Neubauer B. L., Pennington P., Stamm N. B., Toomey R. E. and Russell D. W.: LY191704: a selective non-steroidal inhibitor of human steroid 5α-reductase 1. J. Med. Chem. 36 (1993) 421-423.
21. 21. Rasmusson G. H., Reynolds G. F., Utne T., Jobson R. B., Primka R. L., Berman C. and Brooks J. R.: Azasteroids as inhibitors of rat prostatic 5 alphareductase. J. Med. Chem. 27 (1984) 1690-1701.
22. 22. Bradford M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem. 72 (1976) 248-254.
23. 23. Neubauer B. L., Gray H. M., Hanke C. W., Hirsch K. S., Hsiao K. C., Jones C. D., Kumar M. V., Lawhorn D. E., Lindzey J. V., McQuaid L., Tindall D. J., Toomey R. E., Yao R. C. and Audia J. E.: LY191704 inhibits type I steroid 5α-reductase in human scalp. J. Clin. Endocr. Metab. 81 (1996) 2055-2060.
24. 24. Toomey R. E., Goode R. L., Petrow V. and Neubauer B. L.: An in vivo assay for conversion of testosterone to dihydrotestosterone by rat prostatic steroid 5 alphareductase and comparison of two inhibitors. Prostate 19 (1991) 63-72.
25. 25. Liang T., Cascieri M. A., Cheung A. H., Reynolds G. F. and Rasmusson G. H.: Species differences in prostatic steroid 5α-reductases of rat, dog and human. Endocrinology 117 (1985) 571-579.
26. 26. Harris G., Azzolina B., Baginsky W., Cimis G., Rasmusson G. H., Tolman R. L., Raetz C. R. H. and Ellsworth K.: Identification and selective inhibition of an isozyme of steroid 5 alpha-reductase in human scalp. Proc. Natn. Acad. Sci. U.S.A. 89 (1992) 10787-10791.
27. 27. Segal I. H.: Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems, Wiley and Sons, New York (1975).
28. 28. Delos S., Iehle C., Martin P.-M. and Raynaud J.-P.: Inhibition of the "basic" 5α-reductase (type I) detected in DU145 cells and expressed in insect cells. J. Steroid Biochem. Molec. Biol. 48 (1994) 347-352.
29. 29. Sutkowski D. M., Audia J. E., Bruchovsky N., Goode R. L., Hsiao K. C., McNulty A. M. and Neubauer B. L.: Response of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5α-reductase inhibitor. International Conference on Androgenic Hormones, Prostate Cancer and BPH, New Orleans, LA Prostate (Suppl.) (1996) 6 62-66.
30. 30. Neubauer B. L., Farid N. A., Gray H. R., Hanke C. W., Hirsch K. S., Hsiao K. C., Lawhorn D. E., McQuaid L., Toomey R. E., Valia K. and Audia J. E.: LY191704: Human type I-selective steroid 5α-reductase inhibitor [trans-8-chloro-1,4,4a,5,6,10b-hexahydro-4-methylbenzo [f] quinolin-3(2H)-one]. Drugs Future 20 (1995) 144-147.
31. 31. Stone K. R., Mickey D. D., Wunderli H., Mickey G. H. and Paulson D. F.: Isolation of a human prostatic carcinoma cell line (DU145). Int. J. Cancer 21 (1978) 274-281.
32. 32. Isaacs J. T. and Coffey D. S.: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res. 41 (1981) 5070-5075.
33. 33. Brendler C. B.: Hormonal therapy of prostatic cancer [editorial]. J. Urol. 133 (1985) 650-651.
34. 34. Gormley G. J.: Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors. J. Cell. Biochem. (Suppl.) 16H (1992) 113-117.
35. 35. Presti J. C., Jr., Fair W. R., Andriole G., Sogani P. C., Seidmon E. J., Ferguson D., Ng J. and Gormley G. J.: Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J. Urol. 148 (1992) 1201-1204.
36. 36. Hudson R. W., Moffitt P. M. and Owens W. A.: Studies of the nuclear 5 alpha-reductase of human prostatic tissue: comparison of enzyme activities in hyperplastic, malignant, and normal tissues. Can. J. Biochem. Cell. Biol. 61 (1983) 750-755.
37. 37. Morfin R. F., Leav I., Charles J. F., Cavazos L. F., Ofner P. and Floch H. H.: Correlative study of the morphology and C19-steroid metabolism of benign and cancerous human prostatic tissue. Cancer 39 (1977) 1517-1534.
38. 38. Klein H., Bresse M., Kastendieck H. and Voigt K. D.: Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer. Am. J. Clin. Oncol. (Suppl. 2) 11 (1988) 30-36.
39. 39. Kliman B., Prout G. R., Jr., Maclaughlin R. A., Daly J. J. and Griffin P. P.: Altered androgen metabolism in metastatic prostate cancer. J. Urol. 119 (1978) 623-626.